Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $20.1M | $30.9M | $231K | $28.6M | $27.4M | $26.6M | $60.0M | $434M | $46.0M |
| Revenue growth | — | — | 54.1% | -99.3% | 12293.1% | -4.4% | -2.8% | 125.7% | 624.1% | -89.4% |
| Operating income | -$32.7M | -$37.9M | -$42.3M | -$80.5M | -$64.5M | -$126M | -$131M | -$93.7M | $253M | -$158M |
| Operating margin | — | -188.9% | -136.7% | -34857.6% | -225.4% | -460.0% | -494.2% | -156.1% | 58.2% | -343.6% |
| Net income | -$37.2M | -$37.0M | -$38.9M | -$77.2M | -$66.2M | -$126M | -$127M | -$79.0M | $275M | -$130M |
| Net margin | — | -184.2% | -125.9% | -33414.3% | -231.1% | -458.9% | -479.3% | -131.6% | 63.3% | -282.8% |
| EPS (diluted) | -$5.80 | -$2.09 | -$1.74 | -$2.98 | -$1.92 | -$2.71 | -$2.60 | -$1.39 | $4.23 | -$2.05 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$30.0M | $3.87M | -$49.9M | -$41.5M | -$72.5M | -$108M | -$108M | -$70.2M | $184M | $57.7M |
| Capital expenditures | $347K | $666K | $486K | $967K | $471K | $1.10M | $795K | $609K | $1.35M | $1.59M |
| Free cash flow | -$30.3M | $3.21M | -$50.4M | -$42.5M | -$73.0M | -$109M | -$109M | -$70.8M | $183M | $56.1M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $21.1M | $106M | $82.2M | $33.0M | $117M | $124M | $126M | $187M | $97.2M | $128M |
| Total assets | $94.0M | $164M | $139M | $155M | $324M | $348M | $248M | $358M | $745M | $668M |
| Total liabilities | $6.43M | $43.1M | $27.0M | $75.0M | $44.9M | $47.7M | $32.3M | $21.3M | $69.4M | $53.5M |
| Long-term debt | — | — | — | $9.79M | — | — | — | — | — | — |
| Shareholders' equity | $87.6M | $121M | $113M | $80.0M | $280M | $300M | $216M | $337M | $675M | $615M |
| Retained earnings | -$64.6M | -$102M | -$140M | -$218M | -$284M | -$409M | -$537M | -$616M | -$341M | -$471M |
| Shares (wtd avg diluted) | 16.7M | 21.1M | 23.2M | 27.2M | 34.4M | 46.3M | 49.0M | 56.8M | 65.1M | 63.6M |
Every figure is extracted from Protagonist Therapeutics, Inc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.